A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative Colitis
Latest Information Update: 04 Mar 2026
At a glance
- Drugs Chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Hebei Senlang Biotechnology
Most Recent Events
- 04 Mar 2026 New trial record